Billy Tauzin will leave PhRMA in June - and a lot of insiders around town may not be sorry to see him go.

The list of critics includes Pfizer Chairman Jeff Kindler, whom sources say has had a rocky relationship with the former Louisiana congressman. Kindler, a Democrat, is taking over the chair of PhRMA this spring. (Tauzin said in a statement he is leaving PhRMA voluntarily to pursue other interests.)

Tauzin's role in negotiating the expensive deal to back now-stalled health care reforms with Senate Finance Chairman Max Baucus, D-Mont., and the Obama administration, has sparked other recriminations inside PhRMA. Lobbyists have grumbled increasingly about the wisdom of the Tauzin strategy-- even though early on it looked like legislation could benefit the industry if it passed and drug companies benefitted from millions of new customers. The White House also promised Tauzin that drug importation from Canada would be off table. In return, Tauzin said his industry would contribute about $80 billion over the next decade to help pay for the health care overhaul.

He will leave PhRMA with a lot of work to do on the Hill to repair ties with Republican leaders who were furious that after years of helping drug companies fend off Democratic backed regulations, PhRMA was working closely with the White House. "He's left a reservoir of ill will both with liberal Democrats and conservative Republicans," said one veteran PhRMA hand. 

Further, sources predict that some of Tauzin's key staff at PhRMA who he brought with him to K Street from the Hill, such as his long time spokesman Ken Johnson, will also be leaving PhRMA with Tauzin.

Tauzin has also been criticized for spending a large amount of time outside Washington at his home in Texas.